

For Immediate Release

## Pasture Navigates Industry Headwinds, Maintains Focus on Operational Discipline

- **Revenue impacted by market conditions:** Revenue for 1H2026 declined by 40.6% to US\$4.3M (1H2025: US\$7.2M), reflecting pricing pressure and supply-chain disruptions across key markets during this period.
- **Operational cost pressures weighed on profitability:** Gross profit decreased by 64.2% to US\$0.7M (1H2025: US\$2.0M), as higher logistics costs and operational complexity affected near-term performance.
- **Core fundamentals remain strong:** Despite the challenging period, the Group maintained regulatory compliance, supply reliability, and key customer relationships. The Group stayed invested in its core and emerging markets while deepening the capabilities of its team.

**Singapore, 13 February 2026** - Pasture Holdings Ltd. ("Pasture" or the "Company", and together with its subsidiaries, the "Group"), a global pharmaceutical products and medical supplies and devices company, has announced its unaudited financial results for the six months ended 31 December 2025 ("1H2026") as follows.

### Results Overview

Financial Highlights (US\$'000)	1H2026	1H2025	Change (%)
<b>Revenue*</b>	4,255	7,169	(40.6)
- Pharmaceutical wholesale and drop-shipment	4,121	6,906	(40.3)
- Mask and medical supplies	105	196	(46.4)
<b>Gross profit</b>	719	2,008	(64.2)
<b>Profit/(Loss) before tax</b>	(785)	548	NM
<b>Net Profit (Loss)</b>	(785)	471	NM

*\*Only revenue from key segments is shown here*

In 1H2026 the Group recorded revenue of US\$4.3M, down 40.6% year-on-year, reflecting a challenging operating environment. The decline in revenue which was anticipated due to the impact of tariffs and changes in customs regulations, resulted in lower shipment volumes. The absence of revenue from a government-linked supply contract, which was completed in 1H2025, also contributed to the reduction in revenue in 1H2026.

Gross profit came in lower at US\$0.7M as cost pressures from higher compliance requirements and the complexity of cross-border pharmaceutical shipments led to increased freight and processing expenses. These additional costs were largely absorbed by the Group to maintain regulatory standards and supply continuity.

## **Outlook: Navigating Industry Headwinds with Disciplined Execution**

As a global pharmaceuticals and medical supplies company, the Group's results were impacted by the ongoing economic headwinds, disruptions to trade flows due to evolving US tariff policies, and increasing regulatory and distribution complexities.

These developments have affected customers' procurement timelines, supply chain visibility, and business sentiments across key markets that in turn impacted the Group's operations in 1H2026 despite our early risk mitigation strategies.

We expect elements of this uncertainty to persist into the second half of the financial year. Accordingly, we continue to actively strengthen our resilience and operational agility, in response to evolving conditions.

Notwithstanding the uncertain near-term visibility, our diversified global footprint, deep regulatory expertise, and strong client relationships position us to manage near-term volatility and continue pursuing opportunities arising from global trade realignment and growing healthcare demand, particularly in emerging markets.

**Mr. Lloyd Soong, the Executive Chairman and Chief Executive Officer of Pasture** commented, "This period was not an easy one. We faced pricing pressure, supply-chain disruption, and a more demanding operating environment across our markets. While the Group recorded a net loss, our priority remains resilience first, growth after – ensuring we emerge stronger when external conditions stabilize. We continue to focus on doing the fundamentals well – maintaining supply reliability, staying disciplined on regulatory standards, and standing by our partners and customers. We believe our approach puts us in a strong position to navigate this evolving environment."

##

## About Pasture Holdings Ltd.

Pasture is a Singapore-based, global pharmaceutical products and medical supplies and devices company. Having supplied to over 50 countries, the Group has a comprehensive portfolio of over 1,000 third-party pharmaceutical products and over 1,200 medical supplies and devices. In addition, Pasture develops, markets and sells its own proprietary range of masks under the *Pasture Masks* brand and, as part of its pharmaceutical wholesale and drop-shipment business, specialises in cold-chain management services relating to temperature-sensitive pharmaceutical products. The Group is also involved in other new complementary products and services such as *Hart-S ODS*, its own range of oral disintegrating strips and *furlife*, a mobile application for pet health services.

For more information, please visit <https://pasturegroup.com/>

---

This press release and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"). The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release. The contact person for the Sponsor is Mr. Shervyn Essex, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, [sponsorship@ppcf.com.sg](mailto:sponsorship@ppcf.com.sg).

---